» Articles » PMID: 36191607

Ursolic and Oleanolic Acids in Combination Therapy Inhibit Migration of Colon Cancer Cells Through Down-regulation of the UPA/uPAR-dependent MMPs Pathway

Overview
Publisher Elsevier
Date 2022 Oct 3
PMID 36191607
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Colorectal cancer is one the most lethal cancers worldwide. Since chemotherapy is burdened with harmful effects, agents capable of enhancing the chemotherapeutic effect are being sought. Ursolic acid (UA) and oleanolic acid (OA) were analyzed for such properties. The aim of the study was to evaluate the ability of UA and OA administered individually and in combination with each other and/or a cytostatic drug camptothecin-11 (CPT-11) to limit the viability and migration of colorectal cancer cells.

Materials And Methods: The cytotoxic effect of UA, OA and CPT-11 and impact on normal and cancer cell migration rate were assessed. Furthermore, the effect on factors crucial in cancer metastasis: MMP-2 and -9, uPA/uPAR, and E-cadherin were assessed with ELISA, Western Blotting and immunofluorescence assays. Statistical analysis was performed with One-Way Anova with Dunnett's test.

Results: The studied compounds exhibited the most favorable properties, i.e. they reduced the viability and migration of cancer cells. Furthermore, the secretion, activity, and cellular level of cancer MMP-2 and -9 were decreased, as a result of uPA/uPAR down-regulation. The agents also increased the level of cellular E-cadherin. The effect of the studied agents on normal cells was milder.

Conclusions: The compounds exhibited stronger activity when administered in combination and, combined with CPT-11, enhanced anti-tumorigenic activity of the drug. The migration-limiting activity was based on down-regulation of the uPA/uPAR-dependent MMP pathway. Moreover, UA and OA exhibited a protective effect towards normal cells.

Citing Articles

Oleanolic acid combined with aspirin plays antitumor roles in colorectal cancer via the Akt/NFκB/IκBα/COX2 pathway.

Zhou Y, Lin S, Zhong X, Huang F, Huang J, Xu L Cell Death Discov. 2024; 10(1):504.

PMID: 39695129 PMC: 11655652. DOI: 10.1038/s41420-024-02223-9.


Ursolic acid in colorectal cancer: mechanisms, current status, challenges, and future research directions.

Zhang H, Zhang X, Ma X, Wang X Pharmacol Rep. 2024; 77(1):72-86.

PMID: 39617815 DOI: 10.1007/s43440-024-00684-4.


Cytotoxic Autophagy: A Novel Treatment Paradigm against Breast Cancer Using Oleanolic Acid and Ursolic Acid.

Gupta K, Gao J, Li X, Thangaraju M, Panda S, Lokeshwar B Cancers (Basel). 2024; 16(19).

PMID: 39409987 PMC: 11476055. DOI: 10.3390/cancers16193367.


Genotoxic and Anti-Migratory Effects of Camptothecin Combined with Celastrol or Resveratrol in Metastatic and Stem-like Cells of Colon Cancer.

Moreira H, Szyjka A, Beben D, Siwiela O, Radajewska A, Stankiewicz N Cancers (Basel). 2024; 16(19).

PMID: 39409900 PMC: 11476312. DOI: 10.3390/cancers16193279.


Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems.

Wasim M, Bergonzi M Pharmaceutics. 2024; 16(6).

PMID: 38931816 PMC: 11206505. DOI: 10.3390/pharmaceutics16060692.